The results of a phase 1 clinical trial using antibody 3BNC117 were published a few days ago in the journal, Nature.
In the trial, researchers injected the antibody into 29 volunteers, 17 with HIV and 12 without. The subjects received one intravenous dose of 1, 3, 10, or 30 milligrams of the antibody.
“Among HIV-infected participants, 3BNC117 had the greatest effect on the eight participants who received the highest dose, resulting in significant and rapid decreases in viral load,” the National Institutes of Health (NIH) reported in a news release. “HIV resistance to 3BNC117 was variable, but some individuals remained sensitive … for 28 days.” Continue reading